About ACell
ACell is a company based in Lafayette (United States) founded in 1999 was acquired by Integra LifeSciences in December 2020. ACell has raised $8.7 million across 1 funding round from investors including Integra LifeSciences. The company has 398 employees. ACell operates in a competitive market with competitors including Kerecis, Humacyte, Kitotech Medical, microMend and CUTISS, among others.
- Headquarter Lafayette, United States
- Employees 398
- Stage Public
- SectorsHealthcare
- Website acell.com
- Social LinkedIn
- Acquired by Integra LifeSciences (Dec 2020)
- Legal Name A Cell Inc
- Total Equity Funding$8.7M (USD)
in 1 rounds
- Latest Funding Round$8.7M (USD), Series A
Apr 2011
- Investors
- Employee Count398
- Acquired byIntegra LifeSciences
(Dec 2020)
Funding Insights of ACell
ACell has successfully raised a total of $8.7M through 1 strategic funding round. The most recent funding activity was a Series A round of $8.7 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.7M
- Total Rounds 1
- Last Round Series A — $8.7M
- First Round $8.7M
(Apr 2011)
All 1 funding rounds of ACell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2011 | $8.7M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in ACell
ACell has secured backing from 1 investor. Prominent investors backing the company include Integra LifeSciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified medical devices are developed for healthcare applications. | 1989 | integralife.com | Plainsboro, United States |
Investor details for ACell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ACell
4 dated milestones of ACell across 21 years, from founding to its latest funding, stage changes and deals.
- Founded ACell is founded.
- Funding First funding round of $8.7M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Integra LifeSciences.
Competitors of ACell
ACell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kerecis, Humacyte, Kitotech Medical, microMend and CUTISS, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kerecis.com | 2007 | Isafjordur, Iceland | $93.11M | 150 | Fish-skin acellular dermal matrix technology is provided for wound treatments. | |
| humacyte.com | 2004 | Morrisville, United States | $424.76M | 70 | Human tissue-based products are developed for vascular disease applications. | |
| kitotechmedical.com | 2011 | Seattle, United States | $20.85M | – | Developer of a device to close wounds, lacerations, and surgical incisions | |
| micromendskinclosure.com | 2017 | Seattle, United States | $3.41M | – | Solutions for treating dermatological disorders are provided by microMend. | |
| cutiss.swiss | 2017 | Zurich, Switzerland | $94.37M | – | Personalized skin tissue therapy is developed by CUTISS for surgeries. | |
| polynovo.com | 2004 | Port Melbourne, Australia | – | – | Developer of biodegradable temporising matrix for treating traumatic wounds | |
| tissueregenix.com | 2006 | Swillington, United Kingdom | – | 7 | Developer of regenerative medical devices by using cell technology | |
| acera-surgical.com | 2013 | St. Louis, United States | $6.32M | – | Synthetic electrospun scaffolds are provided for regenerative medical uses. | |
| contraline.com | 2015 | Charlottesville, United States | $18.62M | 7 | Contraline is focused on developing innovative male contraception solutions. |
Detailed competitors of ACell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acell
Complete news archive for ACell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ACell
10 companies that operate in the same segment as ACell (Wound Care), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Developer of advanced haemostat and wound care dressing products | 2008 | Ahmedabad, Gujarat, India | USD 42.71 M | USD 2.88 M | 70 | |
Oxygen-based wound therapy devices are developed for healing non-healing wounds. | 2003 | Waterbeach, Cambridgeshire, United Kingdom | USD 68.39 M | – | – | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M | – | – | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Cold plasma solutions for wound treatment are developed. | 2013 | Eindhoven, Noord-brabant, Netherlands | USD 7.06 M | – | – | |
Point-of-care devices for wound bacterial assessment are provided. | 2013 | Toronto, Ontario, Canada | USD 43.2 M | – | 49 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ACell
ACell was founded in 1999 and raised its 1st funding round 12 years after it was founded.
ACell is headquartered in Lafayette, United States. It is registered at Lafayette, Louisiana, United States.
ACell is a funded company, having raised a total of $8.7M across 1 funding round to date. The company's 1st funding round was a Series A of $8.7M, raised on Apr 2011.
ACell has 398 employees.
ACell was founded in 1999 as a regenerative medicine company focused on tissue repair and remodeling. Extracellular Matrix (ECM) technology, based on the Urinary Bladder Matrix (UBM) platform, is utilized to create products such as Wound Matrix, Burn Matrix, MicroMatrix, Pelvic Floor Matrix, and Surgical Matrix. Operations include development and manufacturing, with headquarters in Columbia and a facility in Lafayette, United States.
ACell has 1 investor. Key investors include Integra LifeSciences.
ACell operates through A Cell Inc.
Yes. ACell was acquired by Integra LifeSciences in December 2020.